# ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCL

> **NCT02141451** · PHASE1,PHASE2 · COMPLETED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 30 (actual)

## Conditions studied

- Diffuse Large B Cell Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Rituximab
- **DRUG:** INCB7839

## Key facts

- **NCT ID:** NCT02141451
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2019-01-23
- **Final completion:** 2019-06
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2020-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02141451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02141451, "ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCL". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT02141451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*